Intravenous Immunoglobulins
View article: PO:23:055 | Overlap of systemic sclerosis and Sjögren’s disease: insights from an Italian case-control study
PO:23:055 | Overlap of systemic sclerosis and Sjögren’s disease: insights from an Italian case-control study Open
Background. Patients with systemic sclerosis (SSc) may refer sicca symptoms, mainly due to glandular fibrosis but also in the setting of coexisting Sjögren’s disease (SjD)[1,2]. This overlap was first described in 1965[3], but available da…
View article: Ultralow Dose Rituximab Combined With <scp>IVIG</scp> Is Safe and Effective in Pemphigus Vulgaris: Single‐Center Review of 24 Patients
Ultralow Dose Rituximab Combined With <span>IVIG</span> Is Safe and Effective in Pemphigus Vulgaris: Single‐Center Review of 24 Patients Open
We present a combined ultralow dose rituximab and intravenous immunoglobulin protocol for the treatment of moderate to severe pemphigus vulgaris which has been proven to be safe and effective in a series of 24 rituximab naïve patients.
View article: Stevens-Johnson syndrome/toxic epidermal necrolysis induced by tislelizumab: a case report and literature review
Stevens-Johnson syndrome/toxic epidermal necrolysis induced by tislelizumab: a case report and literature review Open
Tislelizumab, a programmed cell death-1 inhibitor approved for multiple malignancies, may induce Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)—a rare but potentially fatal severe drug eruption—and early effective interventi…
View article: Disease-Modifying Treatment Options in Very Early Onset Multiple Sclerosis—What Choices Are There for Onset Under 5 Years of Age? A Systematic Review
Disease-Modifying Treatment Options in Very Early Onset Multiple Sclerosis—What Choices Are There for Onset Under 5 Years of Age? A Systematic Review Open
Background/Objectives: Very early pediatric-onset multiple sclerosis (POMS) is rare; clinical studies using disease-modifying treatments (DMTs) have not been performed. Clinicians rely on studies performed at older ages. This review result…
View article: Paediatric pure motor Guillain–Barré syndrome without antecedent infection: An uncommon clinical scenario
Paediatric pure motor Guillain–Barré syndrome without antecedent infection: An uncommon clinical scenario Open
Guillain–Barré syndrome (GBS) is a sudden-onset autoimmune disorder that targets the peripheral nervous system, typically occurring after infections and manifesting as a swiftly advancing, symmetrical muscle weakness. Paediatric GBS is rar…
View article: A rare complication in Schnitzler syndrome: recall urticaria in a patient treated with anakinra—a case report
A rare complication in Schnitzler syndrome: recall urticaria in a patient treated with anakinra—a case report Open
Schnitzler syndrome is a rare acquired autoinflammatory disorder defined by a chronic urticarial rash, monoclonal IgM (or IgG) gammopathy, and systemic features including fever, arthralgia, and elevated inflammatory markers. Interleukin-1 …
View article: Very High Dose Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre UK Study
Very High Dose Immunoglobulin Treatment for Chronic Inflammatory Demyelinating Polyneuropathy: A Multicentre UK Study Open
Background Immunoglobulin dosing is individualised in chronic inflammatory demyelinating polyneuropathy (CIDP). Methods We retrospectively compared differences in presentation/outcomes/side effects in subjects on very high dose immunoglobu…
View article: Efficacy of IVIG in Post-Acute Sequelae of SARS-CoV-2 Infection: Present Evidence and Future Perspectives
Efficacy of IVIG in Post-Acute Sequelae of SARS-CoV-2 Infection: Present Evidence and Future Perspectives Open
Immunomodulatory treatment called intravenous immunoglobulin (IVIG) is used to treat several neuroimmune conditions, such as Guillain-Barré Syndrome, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, and multifocal mot…
View article: Efficacy of IVIG in Post-Acute Sequelae of SARS-CoV-2 Infection: Present Evidence and Future Perspectives
Efficacy of IVIG in Post-Acute Sequelae of SARS-CoV-2 Infection: Present Evidence and Future Perspectives Open
Immunomodulatory treatment called intravenous immunoglobulin (IVIG) is used to treat several neuroimmune conditions, such as Guillain-Barré Syndrome, chronic inflammatory demyelinating polyneuropathy, multiple sclerosis, and multifocal mot…
View article: Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study
Efficacy and safety of efgartigimod versus intravenous immunoglobulin in early intervention of acetylcholine receptor antibody-positive impending myasthenic crisis: A retrospective cohort study Open
Early intervention in impending myasthenic crisis (IMC) is critical to avert life-threatening progression. This study compared the clinical effectiveness and safety of the novel FcRn antagonist efgartigimod versus intravenous immunoglobuli…
View article: The association of gut microbiota with responsiveness to initial high-dose intravenous immunoglobulin therapy in Kawasaki disease
The association of gut microbiota with responsiveness to initial high-dose intravenous immunoglobulin therapy in Kawasaki disease Open
Variations in gut microbiota may contribute to the pathogenesis and treatment response in Kawasaki disease (KD), but their role remains unclear. We analyzed fecal samples from 25 children with acute-phase KD and 9 age-matched healthy contr…
View article: Neutralization Activity of Standard and Hyperimmune Intravenous Immunoglobulins Against Recently Circulating SARS-CoV-2 Variants
Neutralization Activity of Standard and Hyperimmune Intravenous Immunoglobulins Against Recently Circulating SARS-CoV-2 Variants Open
Our study demonstrates that IVIG lots manufactured in 2023–2024 contain neutralizing antibodies against circulating Omicron variants, including KP.3 and XEC. These variants are resistant to all convalescent plasma and IVIG preparations pro…
View article: Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study
Efficacy of Intravenous Immunoglobulin for Systemic Manifestations of Dermatomyositis Beyond Muscular and Cutaneous: Sub-analysis of the ProDERM Study Open
ClinicalTrials. gov identifier, NCT02728752.
View article: Evaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy
Evaluation and treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy Open
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an inflammatory, immune-mediated neuropathy of the peripheral nerves and nerve roots. CIDP is unlikely to be a discrete disease entity, but rather a spectrum of related co…
View article: Comparison of the Efficacy of Intravenous Immunoglobulin with Methylprednisolone as First-line Therapy in Multisystem Inflammatory Syndrome in Children: A Prospective Cohort Study
Comparison of the Efficacy of Intravenous Immunoglobulin with Methylprednisolone as First-line Therapy in Multisystem Inflammatory Syndrome in Children: A Prospective Cohort Study Open
Aims and background: Comparison of the efficacy of methylprednisolone with intravenous immunoglobulin (IVIG) as first-line therapy in multisystem inflammatory syndrome in children (MIS-C). Multisystem inflammatory syndrome in children is t…
View article: Intravenous immunoglobulin as an effective treatment for refractory pemphigus vegetans: A case report
Intravenous immunoglobulin as an effective treatment for refractory pemphigus vegetans: A case report Open
Pemphigus vegetans (PVeg), which affects < 2% of pemphigus cases, presents a therapeutic challenge when refractory to conventional treatments. Herein, we describe the case of a 58-year-old woman diagnosed with Hallopeau-type PVeg who de…
View article: Intravenous Immunoglobulin (IVIG) in COVID-19: A Missed Opportunity?
Intravenous Immunoglobulin (IVIG) in COVID-19: A Missed Opportunity? Open
View article: POS0273 EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN ON PULMONARY MANIFESTATIONS IN PATIENTS WITH DERMATOMYOSITIS: POST-HOC ANALYSIS OF THE ProDERM DATA
POS0273 EFFICACY OF INTRAVENOUS IMMUNOGLOBULIN ON PULMONARY MANIFESTATIONS IN PATIENTS WITH DERMATOMYOSITIS: POST-HOC ANALYSIS OF THE ProDERM DATA Open
View article: D.6 Changes in intravenous or subcutaneous immunoglobulin usage before and after efgartigimod initiation in patients with Myasthenia Gravis
D.6 Changes in intravenous or subcutaneous immunoglobulin usage before and after efgartigimod initiation in patients with Myasthenia Gravis Open
Background: While efgartigimod usage is expected to reduce immunoglobulin (IG) utilization, evidence in clinical practice is limited. Methods: In this retrospective cohort study, patients with gMG treated with efgartigimod for ≥1-year were…
View article: The Effect on Quality of Life of Therapeutic Plasmapheresis and Intravenous Immunoglobulins on a Population of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients with Elevated β-Adrenergic and M3-Muscarinic Receptor Antibodies—A Pilot Study
The Effect on Quality of Life of Therapeutic Plasmapheresis and Intravenous Immunoglobulins on a Population of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients with Elevated β-Adrenergic and M3-Muscarinic Receptor Antibodies—A Pilot Study Open
Background/Objectives: Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating condition with not fully understood causes, though evidence points to immune system involvement and possible autoimmunity. ME/CFS could be…
View article: Chronic intestinal pseudo-obstruction in the course of systemic sclerosis successfully treated with intravenous immunoglobulins and rituximab
Chronic intestinal pseudo-obstruction in the course of systemic sclerosis successfully treated with intravenous immunoglobulins and rituximab Open
Chronic intestinal pseudo-obstruction (CIPO) is an infrequent and menacing complication of systemic sclerosis (Ssc). While researchers report positive impact of rituximab (RTX) on CIPO in paraneoplastic syndrome, no case reports exist for …
View article: Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved
Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved Open
This review aims to explore the role of immunotherapeutic strategies—primarily intravenous immunoglobulin (IVIG), plasma exchange (PLEX), and selected immunomodulatory agents—in the treatment of neurological and psychiatric disorders with …
View article: Intravenous immunoglobulin for the acute treatment of refractory optic neuritis in Japan
Intravenous immunoglobulin for the acute treatment of refractory optic neuritis in Japan Open
Purpose To investigate the usage status and evaluate the efficacy of intravenous immunoglobulin (IVIG) for the acute treatment of optic neuritis (ON) in Japan. Study design Multicenter retrospective case series. Methods The study subjects …
View article: Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved
Efficacy of Intravenous Immunoglobulins and Other Immunotherapies in Neurological Disorders and Immunological Mechanisms Involved Open
Glutamatergic pathway abnormalities are increasingly recognised as central to various neuropsychiatric disorders, including autoimmune encephalitis, schizophrenia, and epilepsy, where autoantibodies targeting NMDA, AMPA, and GluR3 receptor…
View article: A Practical Approach to the Management of Anaphylaxis Induced by the Infusion of Intravenous Immunoglobulins: A Case Report
A Practical Approach to the Management of Anaphylaxis Induced by the Infusion of Intravenous Immunoglobulins: A Case Report Open
Introduction Allergic reactions, including anaphylaxis, are a well-known complication in some patients who receive blood/plasma transfusions and have an immunoglobulin A (IgA) deficiency. Even patients with panhypogammaglobulinemia and def…
View article: Anti-Oxidized Low-Density Lipoprotein Antibodies Before and After Intravenous Immunoglobulin Therapy in Kawasaki Disease ― Evidence for a Potentially Protective Role ―
Anti-Oxidized Low-Density Lipoprotein Antibodies Before and After Intravenous Immunoglobulin Therapy in Kawasaki Disease ― Evidence for a Potentially Protective Role ― Open
This study highlighted the distinct roles of anti-oxidized LDL and anti-HMGB1 antibodies during the acute phase of KD. The increase in anti-oxidized LDL antibodies following IVIG treatment suggests a protective effect, while the transient …
View article: Deciphering the prognostic role of serum immunoglobulin G in Guillain-Barré syndrome during intravenous immunoglobulin treatment
Deciphering the prognostic role of serum immunoglobulin G in Guillain-Barré syndrome during intravenous immunoglobulin treatment Open
Lower increase in IgG levels at 7 days post-treatment is associated with a worse prognosis at 6 months, including a reduced likelihood of walking unaided.
View article: Syncope and New-Onset Bifascicular Block Associated With Intravenous Immunoglobulin in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy
Syncope and New-Onset Bifascicular Block Associated With Intravenous Immunoglobulin in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy Open
View article: Kawasaki Disease in a Preschooler: A Case Study on Timely Diagnosis and IVIG (Intravenous Immunoglobulin) Intervention
Kawasaki Disease in a Preschooler: A Case Study on Timely Diagnosis and IVIG (Intravenous Immunoglobulin) Intervention Open
Background: Kawasaki disease (KD) is an acute, systemic vasculitis predominantly affecting young children and represents the leading cause of acquired heart disease in developed nations. Diagnostic challenges, particularly in resource-limi…
View article: Cost analysis of treatment with therapeutic plasma exchange versus treatment with intravenous immunoglobulins in patients with immune-based neurological diseases. Proposal for optimising the use of plasmatic blood products
Cost analysis of treatment with therapeutic plasma exchange versus treatment with intravenous immunoglobulins in patients with immune-based neurological diseases. Proposal for optimising the use of plasmatic blood products Open
The use of TPE in the first line in pathologies in which the clinical results do not present significant differences with the IGEV, optimises the use of blood products and can lead to economic savings. It is necessary to expand this study …